Skip to content
Search:
Search
Facebook page opens in new window
 
ADCS
Alzheimer's Disease Cooperative Study
ADCSADCS
  • About Us
    • About ADCS
    • Meet the Team
    • ADCS Cores
    • Our Clinical Trials Network
    • Intervention Selection Committee (ISC)
    • Our Steering Committee
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
    • DONATE
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biorepository
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • Steering Committee Members
  • Staff Resources
  • About Us
    • About ADCS
    • Meet the Team
    • ADCS Cores
    • Our Clinical Trials Network
    • Intervention Selection Committee (ISC)
    • Our Steering Committee
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
    • DONATE
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biorepository
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • Steering Committee Members
  • Staff Resources

Daily Archives: February 11, 2019

You are here:
  1. Home
  2. 2019
  3. February
  4. 11

ADCS Director Howard Feldman, MD talks about the T2 Protect trial and a bright future for Alzheimer’s research

Research NewsBy ADCS AdminFebruary 11, 2019
Copyright 2017 Regents of the University of California.
Go to Top